Cart
sales@molnova.com
CPI-169
CAS No. 1450655-76-1
CPI-169( CPI-169 | CPI 169 | CPI169 )
Catalog No. M17305 CAS No. 1450655-76-1
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 65 | In Stock |
|
| 5MG | 114 | In Stock |
|
| 10MG | 162 | In Stock |
|
| 25MG | 356 | In Stock |
|
| 50MG | 530 | In Stock |
|
| 100MG | 755 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCPI-169
-
NoteResearch use only, not for human use.
-
Brief DescriptionCPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
-
DescriptionCPI-169 is a potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2). CPI-169 was shown to inhibit tumor growth in a NHL xenograft model, reducing global H3K27me3.1 It has also been shown to synergize with the B-cell lymphoma inhibitor, ABT-199, to suppress the growth of NHL cell lines.
-
In Vitro——
-
In Vivo——
-
SynonymsCPI-169 | CPI 169 | CPI169
-
PathwayAngiogenesis
-
TargetALK
-
RecptorEZH1| EZH2 WT| EZH2 Y641N
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1450655-76-1
-
Formula Weight528.66
-
Molecular FormulaC27H36N4O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 59 mg/mL. 111.60 mM
-
SMILESCCS(=O)(=O)N1CCC(CC1)C(C)n1c2ccccc2c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c1C
-
Chemical Name(R,Z)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((2-hydroxy-4-methoxy-6-methylpyridin-3-yl)methyl)-2-methyl-1H-indole-3-carbimidic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bradley WD,etal.EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.Chem Biol. 2014 Nov 20;21(11):1463-75.
molnova catalog
related products
-
JH-VIII-157-02
JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM.
-
LDK378
Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity.
-
ALK-IN-26
ALK-IN-26 is an ALK inhibitor with potential anticancer activity, demonstrating antiproliferative effects against glioblastoma and inducing apoptosis, autophagy, and necrosis.
